Condition: Still´s Disease · Sponsor: Novartis Pharmaceuticals
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Cincinnati Childrens Hospital | Cincinnati, Ohio, United States | Active Not Recruiting |
| Legacy Emanuel Research Hosp Portland | Portland, Oregon, United States | Recruiting |
| Novartis Investigative Site | Montreal, Quebec, Canada | Withdrawn |
| Novartis Investigative Site | Montreal, Quebec, Canada | Withdrawn |
| Novartis Investigative Site | Bordeaux, France | Recruiting |
| Novartis Investigative Site | Bron, France | Recruiting |
| Novartis Investigative Site | Le Kremlin-Bicêtre, France | Recruiting |
| Novartis Investigative Site | Lille, France | Recruiting |
| Novartis Investigative Site | Paris, France | Recruiting |
| Novartis Investigative Site | Paris, France | Recruiting |
| Novartis Investigative Site | Sankt Augustin, North Rhine-Westphalia, Germany | Recruiting |
| Novartis Investigative Site | Heidelberg, Germany | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07203001